REG - CRISM Therapeutics - Japanese Patent Grant

CRISM TherapeuticsAnnouncement

20/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260120:nRST5029Pa&default-theme=true

RNS Number : 5029P  CRISM Therapeutics Corporation  20 January 2026

20 January 2026

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Japanese Patent Grant for ChemoSeed

 

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery
company focused on the localised and sustained delivery of chemotherapy drugs,
announces that it has been granted a patent (7800909) by the Japanese Patent
Office.

The patent relates to the Company's lead product, ChemoSeed®, for
chemotherapeutic drug implants and more, particularly, to biodegradable
chemotherapeutic drug implants comprising irinotecan.   ChemoSeed was
invented by Professor Chris McConville, CRISM's Chief Scientific Officer.

The patent covers the manufacturing processes for the preparation of these
chemotherapeutic drug implants and to their use in therapy, in particular in
treating brain tumours such as glioblastoma.

Commenting on the patent grant, CRISM Therapeutics' CEO, Andrew Webb, said:
"We are pleased to have started 2026 by strengthening our IP position through
the grant of this patent in Japan, which we view as a key market. This latest
patent grant broadens our appeal to potential commercial partners.  We remain
confident in CRISM's prospects for the year ahead as we prepare for our
registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in
glioblastoma."

 

-Ends-

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Vadim Alexandre                   CRISM@buchanancomms.co.uk

                                 Adam Cowl
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

CRISM will initiate its registration-grade Phase 2 clinical trial of
irinotecan-ChemoSeed™ in patients with surgically resectable glioblastoma in
Q1 2026.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXFNFSXKEFA



            Copyright 2019 Regulatory News Service, all rights reserved